Clinical Trials Directory

Trials / Completed

CompletedNCT03254966

Study of SHR0302 Tablets (SHR0302) as Monotherapy in Active Rheumatoid Arthritis (RA) Patients

Randomized, Double-blind, Placebo-controlled, Multicenter, Phase II Study to Assess the Safety and Efficacy of SHR0302 in Patients With Moderate to Severe Active Rheumatoid Arthritis

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
194 (actual)
Sponsor
Jiangsu HengRui Medicine Co., Ltd. · Industry
Sex
All
Age
18 Years – 70 Years
Healthy volunteers
Not accepted

Summary

To evaluate the safety and efficacy of SHR0302 tablets (SHR0302) in subjects with moderate to severe active rheumatoid arthritis.

Conditions

Interventions

TypeNameDescription
DRUGSHR0302Oral tablets
DRUGPlaceboOral tablets

Timeline

Start date
2017-11-24
Primary completion
2019-04-16
Completion
2019-10-12
First posted
2017-08-21
Last updated
2021-09-30

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT03254966. Inclusion in this directory is not an endorsement.

Study of SHR0302 Tablets (SHR0302) as Monotherapy in Active Rheumatoid Arthritis (RA) Patients (NCT03254966) · Clinical Trials Directory